The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this present proposal is to examine the efficacy of GLP-1 administered to control blood glucose in critically ill patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Liver Glycogen and Hypoglycemia in Humans

NCT03241706

Hypoglycemia; Iatrogenic

ACTIVE_NOT_RECRUITING PHASE1

Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study

NCT00288743

Critically Ill Patients

COMPLETED PHASE2

Degludec Insulin Use in Critically Ill Patients

NCT06056167

Diabetes Mellitus Critical Illness Hyperglycemia

COMPLETED NA

Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia

NCT06178874

Glycemic Control Insulin Critical Illness

COMPLETED NA

Study of High Blood Sugars and Insulin in Hospitalized, Critically Ill Children

NCT00487006

Critical Illness Hyperglycemia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients whom on admission to the ICU (surgical, burn, \& cardiac) who are expected to receive intensive insulin therapy for at least 72 hours are eligible to be enrolled. Once enrolled, the patients will be randomized to one of two groups: the experimental (intravenous GLP-1 infusion for 72 hours) or control groups (intravenous 0.9% sodium chloride (NaCl) infusion for 72 hours) in a double masked fashion. While enrolled, all patients will receive standard-of-care insulin therapy. Both groups will be maintained on the standard ICU specific protocol for glucose control.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critically Ill Hypoglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GLP-1

Group Type EXPERIMENTAL

Glucagon-Like Peptide-1

Intervention Type DRUG

5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.

Saline

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type DRUG

5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glucagon-Like Peptide-1

5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.

Intervention Type DRUG

Saline

5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GLP-1

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women age \> 21 to 75 years of age.
* All subjects who meet ICU specific criteria for inclusion in their glucose protocol and placed on insulin infusion protocol as standard of care.
* Able to obtain patient or proxy consent.